Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
Key Highlights
- ➤Sildenafil Cream presentation scheduled October 9 at SMSNA’s Annual Fall Scientific Meeting
- ➤71 mg topical dose produced approximately 187-fold lower peak sildenafil levels than 50 mg oral dose
- ➤Systemic sildenafil exposure was approximately 33- to 34-fold lower with topical treatment
- ➤All treatment-emergent adverse events were mild, with no serious events or discontinuations
- ➤Daré is advancing Sildenafil Cream toward FDA’s 505(b)(2) pathway for FSAD
Expert Statements
Annie Thurman, Medical Director of Daré Bioscience
“These findings provide additional clinical evidence supporting the rationale for topical delivery of sildenafil and the potential for substantially lower systemic exposure compared with oral administration.”
Annie Thurman, Medical Director of Daré Bioscience
“As a physician and clinical researcher focused on women’s health, I believe understanding this data on the pharmacokinetic and potential safety profile of our proprietary formulation in men is an important component of advancing Sildenafil Cream as a potential treatment for women with female sexual arousal disorder.”
SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that clinical data from a Phase 1 study that evaluated the Company’s proprietary Sildenafil Cream, 3.6% investigational product (Sildenafil Cream) will be presented at the Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA), taking place October 8-11, 2026, in Orlando, Florida.
Annie Thurman, MD, FACOG, Medical Director of Daré Bioscience, will present “An Open-Label, Single-Dose, Randomized, Parallel-Cohort Study of the Safety and Relative Bioavailability of Topical Sildenafil Cream, Versus Oral Sildenafil in Healthy Male Adults” during the Innovations in Sexual Medicine Abstracts session on Friday, October 9, 2026. A copy of the presentation will be made available through the Presentations, Events & Webcasts page of the Investors section of the Company’s website (darebioscience.com). The poster will be accessible for approximately 30 days after Dr. Thurman’s live presentation.
Get started
Create a free account to read the full story.